Preclinical studies have demonstrated that the novel hepatocellular carcinoma-selective HDAC inhibitor STR-V-53 not only inhibits HDAC activity and upregulates PD-L1 expression in tumor cells but also significantly enhances CD8+ T cell infiltration. Here, HDAC9 is linked to hepatocellular carcinoma.